Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 276.00
Bid: 271.00
Ask: 276.00
Change: -1.00 (-0.36%)
Spread: 5.00 (1.845%)
Open: 277.00
High: 280.00
Low: 274.00
Prev. Close: 277.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 02nd Apr 2014 08:48

Aberdeen Asset Management: Canaccord Genuity reduces target price from 540p to 460p, while its buy recommendation is kept.Anglo American: JP Morgan ups target price from 1260p to 1300p, while leaving its underweight rating unchanged.Aviva: JP Morgan raises target price from 528p to 570p maintaining an overweight rating.Beazley: JP Morgan ups target price from 238p to 258p and keeps a neutral rating.Capital & Counties Properties: Liberum Capital takes target price from 351p to 377p maintaining a hold recommendation.Daily Mail & General Trust: Deutsche Bank moves target price from 630p to 640p, but still recommends its sell recommendation.Domino's Pizza: N+1 Singer raises target price from 480p to 535p retaining its hold recommendation.EMIS: Panmure Gordon increases target price from 731p to 820p and stays with its buy recommendation.First Group: Investec places its target price (prev.: 160p) under review, while keeping its buy recommendation.GlaxoSmithKline: Liberum Capital reduces target price from 1600p to 1500p and retains a hold recommendation.Griffin Mining: Panmure Gordon shifts target price from 111p to 115p and keeps a buy recommendation.Hikma Pharmaceuticals: Panmure Gordon ups target price from 1375p to 1400p maintaining a hold recommendation.Hutchison China Meditech: Panmure Gordon increases target price from 750p to 950p and stays with its buy recommendation.ICAP: JP Morgan cuts target price from 379p to 364p retaining its neutral rating.IP Group: Numis raises target price from 144p to 273p and upgrades from hold to buy.Man Group: Canaccord Genuity moves target price from 110p to 115p and keeps a buy recommendation.Minoan Group: WH Ireland shifts target price from 15p to 20p and stays with its strong buy recommendation.Morrison (Wm): HSBC Holdings cuts target price from 200p to 160p maintaining an underweight rating.Office2Office: WH Ireland upgrades from outperform to buy with a target price of 42p.Prudential: JP Morgan moves target price from 1028p to 1038p, while its underweight rating is kept.Reckitt Benckiser: JP Morgan reduces target price from 4450p to 4250p and stays with its neutral rating.Resolution: JP Morgan cuts target price from 370p to 358p and maintains its neutral rating.Rio Tinto: JP Morgan reduces target price from 4600p to 4500p keeping an overweight rating.Shanks Group: Goldman Sachs cuts target price from 145p to 122p downgrading to neutral.St. James's Place: JP Morgan increases target price from 868p to 909p and reiterates its overweight rating.Tesco: HSBC Holdings cuts target price from 300p to 260p and reiterates an underweight rating.Vedanta Resources: JP Morgan lowers target price from 1120p to 1100p and retains its overweight rating.WEIR Group: Canaccord Genuity raises target price from 2500p to 3000p and reiterates a buy recommendation.
More News
20 Jan 2022 11:03

Hutchmed begins phase one study for potential tumour treatment

Hutchmed begins phase one study for potential tumour treatment

Read more
13 Jan 2022 09:10

TOP NEWS: Retailer ASOS now to be seen on London Main Market

TOP NEWS: Retailer ASOS now to be seen on London Main Market

Read more
12 Jan 2022 11:37

Hutchmed gains breakthrough therapy designation in China for HMPL-523

Hutchmed gains breakthrough therapy designation in China for HMPL-523

Read more
10 Jan 2022 09:23

Hutchmed begins phase one study for potential cancer treatment

Hutchmed begins phase one study for potential cancer treatment

Read more
6 Dec 2021 10:44

Hutchmed completes patient enrolment for cancer drug study

Hutchmed completes patient enrolment for cancer drug study

Read more
3 Dec 2021 13:23

Two Hutchmed drugs included in China's 2022 reimbursement list

(Sharecast News) - Hutchmed China announced on Friday that, following negotiations with the China National Healthcare Security Administration (NHSA), from 1 January the updated National Reimbursement Drug List (NRDL) will continue to include 'Elunate', or fruquintinib, and would now include 'Sulanda', or surufatinib.

Read more
3 Dec 2021 09:54

Two Hutchmed drugs included on China's state approved medicines list

Two Hutchmed drugs included on China's state approved medicines list

Read more
24 Nov 2021 11:35

Hutchmed China shares rise on Orphathys and Tagrisso Phase 3 study

Hutchmed China shares rise on Orphathys and Tagrisso Phase 3 study

Read more
1 Nov 2021 09:14

TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal

TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal

Read more
28 Oct 2021 21:59

IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug

IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug

Read more
29 Sep 2021 11:08

Hutchmed China sells joint venture stake for USD169 million

Hutchmed China sells joint venture stake for USD169 million

Read more
21 Sep 2021 10:51

Hutchmed starts drug combination trial for neuroendocrine tumours

Hutchmed starts drug combination trial for neuroendocrine tumours

Read more
20 Sep 2021 09:09

Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors

Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors

Read more
13 Sep 2021 10:22

Hutchmed China's amdizalisib secures breakthrough therapy designation

Hutchmed China's amdizalisib secures breakthrough therapy designation

Read more
8 Sep 2021 13:49

Hutchmed, Astra launch drug combination trial to treat lung cancer

Hutchmed, Astra launch drug combination trial to treat lung cancer

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.